Research

NSCLC

First Line
(Dartmouth)

Phase III Study of Taxotere and Carboplatin Versus Taxotere and Gemcitabine in Patients with Advanced Non-Small Lung Cancer

SCLC

First Line

A Randomized Phase II Trial of ALIMTA/Cisplatin and ALIMTA/Carboplatin in Extensive Stage Small Cell Lung Cancer

Colorectal

First Line

TREE 2

A Randomized, Prospective Study Comparing Three Regimens of Eloxatin™ Plus Fluoropyrimidine and Avastin™ for the Evaluation of Safety and Tolerability in First Line Treatment of Patients with Advanced Colorectal Cancer

Second Line

EPIC

CA225006: A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan, and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma

EXPLORE

CA225-014: A Phase III Randomized Multicenter Study of Cetuximab, Oxalipatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Patient with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma

Third Line

For patients who have progressed after CPT-11, 5FU or Xeloda and Oxaliplatin:

CA225

Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab (C225) , in Patients with Stage IV Colorectal Carcinoma Who Failed All Standard Therapy: An Access Protocol

Prostate Hormone Refractory

(Dendreon)

A Randomized, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells (Provenge™, APC8015) for Asymptomatic Metastatic Hormone-Refractory Prostate Cancer

(Medimmune)

Phase II, Randomized, Open –Label, Three-Arm, Multicenter Study of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Combination with Weekly Docetaxel + Low Dose Estramustine and Zoledronic Acid in the Treatment of Patients with Androgen-Independent Prostate Cancer that has Metastasized to Bone

Pancreatic

First Line

(OCOG/Lorus)

A Phase III, Double-blind, Multicenter, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy or Virulizin® plus Gemcitabine versus Placebo plus Gemcitabine; Optional Second-line Therapy May Include Continuation of Virulizin® or Placebo, Alone or in Combination with 5-Fluorouracil

Breast

Second Line

(GSK)

Epothilone

Second Line

CA 163048:
A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine VersusCapecitabine Alone in Patients with Advanced Breast Cancer Previously Treated with an Anthracycline and a Taxane

Third Line

An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin ®-Containing Regimens. Patients must have also received Anthracycline, taxane and xeloda